Cardinal Health excelled in Q2, reporting revenue of $66 billion (+19% YoY) and non-GAAP EPS of $2.63 (+36%). They raised fiscal 2026 EPS guidance to $10.15–$10.35, citing strong performance in Pharmaceutical and Specialty Solutions, with revenue up 19% to $61 billion.

GMPD and other businesses saw significant growth, with GMPD profit doubling, and other revenues and segment profit increasing by 34% and 52%, respectively. The company completed $375 million of buybacks in Q2 and maintains $3.0–$3.5 billion adjusted free cash flow guidance.

Cardinal Health’s fiscal second-quarter results included total revenue of $66 billion, up 19% YoY. Gross margin dollars increased 24%, while operating earnings were up 38%. The company reported non-GAAP diluted EPS of $2.63, a 36% increase from the previous year.

Pharmaceutical and Specialty Solutions revenue increased by 19% to $61 billion, driven by strong demand across the portfolio. Segment profit rose by 29%, with multiple drivers contributing to the growth. CEO Jason Hollar emphasized the strategic priority of specialty and reiterated expectations for revenue to exceed $50 billion in fiscal 2026.

Read more at Yahoo Finance: Cardinal Health Q2 Earnings Call Highlights